Unlocking the Mystery of Long COVID: Flinders University Takes the Lead
The battle against COVID-19 continues, but a new challenge emerges from its aftermath. Even as some move on, many still grapple with the enigma of Long COVID. Flinders University steps forward with two crucial projects, armed with over $3 million in funding from the Medical Research Future Fund (MRFF), to address this growing concern.
Post-Acute Sequelae of COVID-19 (PASC), or Long COVID, affects an estimated 6% of those infected, according to the World Health Organization. This condition has left a lasting mark on Australia's health and aged care systems. Flinders University's researchers are determined to make a difference.
Professor Kate Laver spearheads a project focusing on Australia's aged care sector, which has been particularly vulnerable to the effects of COVID-19. With $2,106,718.10 in funding, her team will trial a novel care model for frail older Australians who are more susceptible to Long COVID. This model aims to enhance recovery and improve overall health outcomes.
"The aged care sector has been significantly affected by COVID-19, and we're still witnessing the consequences," Professor Laver explains. "Frail older individuals face a longer recovery period and a higher risk of Long COVID, which can severely impact their independence and quality of life."
But here's where the project gets innovative: By collaborating directly with aged care organizations, the team will not only assess the effectiveness of the PASC model but also upskill the workforce, ensuring the model's adaptability and sustainability.
Meanwhile, Professor David Lynn's project delves into the heart of the mystery: With $995,343.92 in funding, his team aims to unravel the causes of Long COVID. This is crucial, as PASC affects millions worldwide, causing fatigue, illness, and cognitive issues.
"We must identify the root causes to develop effective treatments," Professor Lynn emphasizes. "Although studies have revealed various immunological and neurological changes linked to PASC, we're still in the dark about which of these changes are the primary culprits."
And this is where it gets controversial: Recent research suggests that metformin, a common type 2 diabetes medication, may significantly reduce the risk of Long COVID. Professor Lynn's team will investigate the effects of metformin on Long COVID patients, potentially uncovering new insights into the condition's underlying causes.
These projects, funded under the MRFF's Emerging Priorities and Consumer Driven Research Initiative, promise to shed light on Long COVID and offer hope to those affected. But will these efforts be enough? What other strategies might be needed to fully address this complex issue? Share your thoughts in the comments below.
